Influence of Fractionation Scheme and Tumor Location on Toxicities After Stereotactic Body Radiation Therapy for Large (≥5 cm) Non-Small Cell Lung Cancer: A Multi-institutional Analysis

National Comprehensive Cancer Network. Non-small cell lung cancer. Version 1. Available at: www.nccn.org/professionals/physician_gls/PDF/nsclc.pdf. Accessed March 24, 2016. Timmerman, 2010, Stereotactic body radiation therapy for inoperable early stage lung cancer, JAMA, 303, 1070, 10.1001/jama.2010.261 Simone, 2013, Stereotactic body radiation therapy for lung cancer, Chest, 143, 1784, 10.1378/chest.12-2580 Chang, 2015, Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: A pooled analysis of two randomised trials, Lancet Oncol, 16, 630, 10.1016/S1470-2045(15)70168-3 Verma, 2015, Stereotactic radiotherapy versus surgery for early-stage operable lung cancer: More questions than answers, J Natl Compr Canc Netw, 13, 1293, 10.6004/jnccn.2015.0155 Simone, 2015, Additional data in the debate on stage I non-small cell lung cancer: Surgery versus stereotactic ablative radiotherapy, Ann Transl Med, 3, 172 Verma, 2017, Stereotactic body radiation therapy and the influence of chemotherapy on overall survival for large (≥5 centimeter) non-small cell lung cancer, Int J Radiat Oncol Biol Phys, 97, 146, 10.1016/j.ijrobp.2016.09.036 Aberle, 2011, Reduced lung-cancer mortality with low-dose computed tomographic screening, N Engl J Med, 365, 395, 10.1056/NEJMoa1102873 Verma, 2015, Lung cancer: Implementing lung-cancer screening—oncological ‘grey areas’, Nat Rev Clin Oncol, 12, 256, 10.1038/nrclinonc.2015.65 Verma, 2015, Treatment costs of early-stage lung cancers detected by low-dose computed tomography screening, Int J Radiat Oncol Biol Phys, 93, 207, 10.1016/j.ijrobp.2015.03.036 Verma, 2015, Medicare approves coverage for lung cancer screening: The case for symptomatic screening, JAMA Oncol, 1, 1027, 10.1001/jamaoncol.2015.2165 Woody, 2015, Stereotactic body radiation therapy for non-small cell lung cancer tumors greater than 5 cm: Safety and efficacy, Int J Radiat Oncol Biol Phys, 92, 325, 10.1016/j.ijrobp.2015.01.045 Verma V, Shostrom VK, Kumar SS, et al. Multi-institutional experience of stereotactic body radiotherapy for large (≥5 centimeters) non-small cell lung tumors. Cancer. 2016 Oct 14. http://dx.doi.org/10.1002/cncr.30375. Brown, 2014, The tumor radiobiology of SRS and SBRT: Are more than the 5 R's involved?, Int J Radiat Oncol Biol Phys, 88, 254, 10.1016/j.ijrobp.2013.07.022 Alite, 2016, Local control dependence on consecutive vs. nonconsecutive fractionation in lung stereotactic body radiation therapy, Radiother Oncol, 121, 9, 10.1016/j.radonc.2016.07.026 Yazici, 2013, A simple strategy to decrease fatal carotid blowout syndrome after stereotactic body reirradiation for recurrent head and neck cancers, Radiat Oncol, 8, 242, 10.1186/1748-717X-8-242 King, 2012, Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer, Int J Radiat Oncol Biol Phys, 82, 877, 10.1016/j.ijrobp.2010.11.054 Corradetti, 2013, A moving target: Image guidance for stereotactic body radiation therapy for early-stage non-small cell lung cancer, Pract Radiat Oncol, 3, 307, 10.1016/j.prro.2012.10.005